


# Summary of National Guidance for Lipid Management for Primary and Secondary Prevention of CVD

## INITIAL CONSIDERATIONS:

- Measure non-fasting **full lipid profile** (Total cholesterol, HDL-C, non-HDL-C, triglycerides) and HbA1c as part of an initial baseline assessment.
- Consider secondary causes of hyperlipidaemia and manage as needed.
- Ensure appropriate baseline and follow up tests as detailed on page 2. Measure BMI.
- Identify and exclude people with contraindications/drug interactions
- If non-fasting triglyceride above 4.5mmol/L see page 2.

## PRIMARY PREVENTION

Consider statin therapy for adults who do not have established CVD but fall into the categories below. Use QRISK risk assessment tool where appropriate (see page 2, 'Primary Prevention Risk Assessment')



Identify and address all modifiable risk factors - smoking, diet, obesity, alcohol intake, physical activity, blood pressure and HbA1c.

Consider additional risk factors, if present, together with QRISK score (treated for HIV, severe mental illness, taking medicines that cause dyslipidaemia, systemic inflammatory disorder (e.g. SLE), impaired fasting glycaemia, recent change in risk factors)

## PRIMARY PREVENTION

If lifestyle modification is ineffective or inappropriate offer statin treatment.  
**Atorvastatin 20mg OD**

- Measure full lipid profile again after 3 months (non-fasting).
- High intensity statin treatment should achieve reduction of non-HDL-C > 40% from baseline. If not achieved after 3 months;
  - discuss treatment adherence, timing of dose, diet and lifestyle
  - If at higher risk (based on comorbidities, risk score or clinical judgement – see page 2 'Additional Risk Factors') consider increasing the dose every 2-3 months up to a maximum dose of atorvastatin 80mg OD.
  - For how to increase in people with CKD see 'Special Patient Populations' (page 2).

- If patients on a high-intensity statin have side effects, offer a lower dose or an alternative statin (see page 2 'Statin Intensity Table')
- If maximum tolerated dose of statin does not achieve non-HDL-C reduction > 40% of baseline value after 3 months consider adding Ezetimibe 10mg OD (NICE TA385)
- If recommended statin treatment is contraindicated or not tolerated;
  - See AAC Statin Intolerance Algorithm for advice regarding adverse effects ([click here](#))
  - Ezetimibe 10mg monotherapy may be considered. Assess response after 3 months

If non-HDL-C reduction remains < 40% of baseline despite maximal tolerated lipid lowering therapy (including people with intolerances and contraindications) consider referral to specialist lipid management clinic according to local arrangements

## SEVERE HYPERLIPIDAEMIA

If TC>7.5mmol/L and/or LDL-C >4.9mmol/L and/or non-HDL-C >5.9mmol/L, a personal and/or family history of confirmed CHD (<60 years) and with no secondary causes: suspect Familial Hypercholesterolaemia (Possible Heterozygous FH)  
Do not use QRISK risk assessment tool

## DIAGNOSIS AND REFERRAL

Take fasting blood for repeat lipid profile to measure LDL-C.  
Use the **Simon Broome** or **Dutch Lipid Clinic Network (DLCN)** criteria to make a **clinical diagnosis of FH**.  
Refer to Lipid Clinic for further assessment if **clinical diagnosis of FH** or if TC>9.0mmol/L and/or LDL-C >6.5mmol/L and/or non-HDL-C >7.5mmol/L or Fasting triglycerides > 10mmol/L (regardless of family history) (page 2)

## TREATMENT TARGETS IN FH

If clinical diagnosis of FH and/or other risk factors present follow the recommended treatment management pathway for primary or secondary prevention as for non-FH, **BUT**  
*Aim to achieve at least a 50% reduction of LDL-C (or non-fasting non-HDL-C) from baseline.*

## Consider specialist referral for further treatment and/or consideration of PCSK9i therapy IF

- they are assessed to be at very high risk of a coronary event\*\*
  - OR therapy is not tolerated
  - OR LDL-C remains >5mmol/L (primary prevention)
  - OR LDL-C remains >3.5mmol/L (secondary prevention)
- despite maximal tolerated statin and Ezetimibe therapy.

\*\*defined as any of the following:  
• Established coronary heart disease.  
• Two or more other CVD risk factors

## SECONDARY PREVENTION

Offer statin therapy to adults with CVD, this includes angina, previous MI, revascularisation, stroke or TIA or symptomatic peripheral arterial disease. Do not delay statin treatment if a person has acute coronary syndrome. Take a lipid sample on admission (within 24 hours)

Identify and address all modifiable risk factors - smoking, diet, obesity, alcohol intake, physical activity, blood pressure and HbA1c.

## SECONDARY PREVENTION

Do not delay statin treatment in secondary prevention while managing modifiable risk factors. Prescribe a high intensity statin:  
**Atorvastatin 80mg OD**  
Use a lower dose of Atorvastatin if there is a potential drug interaction, high risk of or experiencing adverse effects, or patient preference.  
Offer Atorvastatin 20mg if CKD (people with GFR< 60 mL/min/1.73m<sup>2</sup>).

- Measure full lipid profile again after 3 months (non-fasting).
- High intensity statin treatment should achieve reduction of non-HDL-C > 40% from baseline. If not achieved after 3 months
  - discuss treatment adherence, timing of dose, diet and lifestyle measures
  - If started on less than atorvastatin 80mg and the person is judged to be at higher risk (based on comorbidities, risk score or clinical judgement – see page 2 'Additional Risk Factors'), consider increasing to 80mg Atorvastatin. For how to increase in people with CKD see 'Special Patient Populations' (page 2).
- If non-HDL-C baseline value is not available\*, consider target non-HDL-C < 2.5mmol/L (approximately equivalent to LDL-C < 1.8mmol/L) as recommended by Joint British Societies (JBS3).  
*\*this scenario is not covered by NICE CG181*
- If patients on a high-intensity statin have side effects, offer a lower dose or an alternative statin (see page 2 'Statin Intensity Table')

- If maximum tolerated dose of statin does not achieve non-HDL-C reduction > 40% of baseline value and/or non-HDL-C < 2.5mmol/L after 3 months consider adding Ezetimibe 10mg OD (NICE TA385)
- If recommended statin treatment is contraindicated or not tolerated
  - See AAC Statin Intolerance Algorithm for advice regarding adverse effects ([click here](#))
  - Ezetimibe 10mg monotherapy may be considered. Assess response after 3 months
  - Ezetimibe 10mg/Bempedoic acid 180 mg combination may be considered when ezetimibe alone does not control non-HDL-C/LDL-C well enough. (NICE TA694)

If non-HDL-C > 4.0mmol/L despite maximal tolerated lipid lowering therapy (including people with intolerances and contraindications), arrange a **fasting blood test** for LDL-C measurement and if **PCSK9i eligibility criteria** (see page 2 'Specialist Services') are met, refer for confirmation and initiation of PCSK9i (NICE TA 393, 394) according to local arrangements

## MANAGEMENT

This guidance applies to new patients and may also be taken into consideration for those already on statins at their annual review. If 40% reduction of non-HDL-C not achieved, offer high intensity statins. Discuss with people who are stable on a low- or medium-intensity statin the likely benefits and potential risk of side effects if changed to a high-intensity statin when they have a medication review and agree with the person whether a change is needed.

If statin therapy is contraindicated, not tolerated or not effective, consider first ezetimibe, then ezetimibe/bempedoic acid, then PCSK9 inhibitor. Use of ezetimibe/bempedoic acid is not precluded when prior low-dose statin is used due to intolerance to higher-intensity statin (check SPC for interactions). Do not offer a fibrate, nicotinic acid, bile acid binder or omega-3 fatty acids alone or in combination with statin, for the prevention of CVD (Check NICE CG181 for exceptions).

## PRIMARY PREVENTION RISK ASSESSMENT

**QRISK3** is the current version of the QRISK calculator. [www.qrisk.org/three](http://www.qrisk.org/three)

- Do not use this risk assessment tool for people with established CVD or those who are at high risk of developing CVD because of FH or other inherited disorders of lipid metabolism.
- Do not use a risk assessment tool to assess CVD risk in people with type 1 diabetes, or eGFR less than 60 mL/min/1.73 m<sup>2</sup> and/or albuminuria.
- Consider people aged ≥ 85 at increased risk of CVD because of age alone particularly people who smoke or have raised BP.

### Additional Risk Factors

Note, standard CVD risk scores including QRISK may underestimate risk in people who have additional risk because of underlying medical conditions or treatments. These groups include the following groups of people;

- severe obesity (BMI>40kg/m<sup>2</sup>) increases CVD risk
- treated for HIV
- serious mental health problems
- taking medicines that can cause dyslipidaemia such as antipsychotic medication, corticosteroids or immunosuppressant drugs
- autoimmune disorders such as systemic lupus erythematosus, and other systemic inflammatory disorders
- non-diabetic hyperglycaemia
- significant hypertriglyceridaemia (fasting triglycerides 4.5-9.9mmol/L)
- recent risk factor changes e.g. quit smoking, BP or lipid treatment

Consider socio-economic status as an additional factor contributing to CVD risk.

**If QRISK < 10% over the next 10 years - Give lifestyle advice and ensure regular review of CVD risk in line with guidance.**

## SPECIAL PATIENT POPULATIONS

### Type 1 Diabetes

While NICE recommends offering statins to patients with Type 1 diabetes as detailed in the algorithm, it also states to consider statins in all adults with type 1 diabetes.

### Chronic Kidney Disease

Offer atorvastatin 20mg for the primary or secondary prevention of CVD to people with CKD (eGFR less than 60 mL/min/1.73m<sup>2</sup> and/or albuminuria)

Increase the dose if a greater than 40% reduction in non-HDL-C is not achieved and eGFR is 30 mL/min/1.73m<sup>2</sup> or more.

Agree the use of higher doses with a renal specialist if eGFR is less than 30 mL/min/1.73m<sup>2</sup>

## ABBREVIATIONS

**CVD:** cardiovascular disease

**FH:** Familial Hypercholesterolaemia

**SPC:** summary of product characteristics

**non-HDL-C:** non-high density lipoprotein cholesterol

**LDL-C:** low density lipoprotein cholesterol

**PCSK9i:** proprotein convertase subtilisin kexin 9 inhibitor

**CKD:** chronic kidney disease

**TC:** total cholesterol

**ALT:** alanine aminotransferase

**AST:** aspartate aminotransferase

**OD:** once daily

Authors: Dr Rani Khatib & Dr Dermot Neely on behalf of the AAC Clinical Subgroup. June 2021. Review date: June 2022. Pathway approved by NICE July 2021.

## STATIN INTENSITY TABLE

Statin dose mg/day	Approximate reduction in LDL-C				
	5	10	20	40	80
Fluvastatin			21%	27%	33%
Pravastatin		20%	24%	29%	
Simvastatin		27%	32%	37%	42%
Atorvastatin		37%	43%	49%	55%
Rosuvastatin	38%	43%	48%	53%	
Atorvastatin + Ezetimibe 10mg		52%	54%	57%	61%

**Low intensity statins** will produce an LDL-C reduction of 20-30%

**Medium intensity statins** will produce an LDL-C reduction of 31-40%

**High intensity statins** will produce an LDL-C reduction above 40%

**Simvastatin 80mg** is not recommended due to risk of muscle toxicity

- **Rosuvastatin** may be used as an alternative to Atorvastatin if compatible with other drug therapy. Lower starting dose maybe needed in some. See BNF.
- Low/medium intensity statins and should only be used in intolerance or drug interactions.
- **Ezetimibe** when combined with any statin is likely to give greater reduction in non-HDL-C/LDL-C than doubling the dose of the statin.
- **PCSK9i** (NICE TA393,394) alone or in combination with statins or Ezetimibe produce an additional LDL-C reduction of approximately 50% (range 25-70%).
- **Bempedoic acid** when combined with ezetimibe (TA694) produces an additional LDL-C reduction of approximately 28% (range 22-33%) but the long-term treatment effect of bempedoic acid is uncertain.

## MONITORING

### Baseline Measurements

In addition to full lipid profile, measure renal, thyroid and liver profiles (including albumin) and HbA1c to exclude secondary causes and co-morbidities. Measure baseline liver transaminase (ALT or AST) before starting a statin. Measure CK if unexplained muscle pain before starting a statin. CK should not be measured routinely especially if a patient is asymptomatic.

	Primary Prevention		Secondary prevention	
	Lipid Profile	ALT or AST	Lipid Profile	ALT or AST
Baseline	✓	✓	✓	✓
3 months	✓	✓	✓	✓
6-9months	If <40% non-HDL-C reduction, up titration required. Repeat full lipid profile and ALT or AST within 3 months of each up-titration of statin dose or addition of Ezetimibe as required			
12 months	✓	✓	✓	✓
Yearly	✓*		✓*	

Provide annual medication reviews for people taking statins to discuss effectiveness of therapy, medicines adherence, lifestyle modification and address CVD risk factors.

\*Consider an annual non-fasting **full lipid profile** to inform the discussion around effectiveness of lipid lowering therapy and any medicines non-adherence.

### Monitoring

Repeat full lipid profile is non-fasting.

Measure liver transaminase within 3 months of starting treatment and then within 3 months of every additional up titration and then again at 12 months, but not again unless clinically indicated.

If ALT or AST are greater than 3 times the upper limit of normal then do not initiate a statin or discontinue statin therapy already prescribed and repeat the LFTs in a month.

If ALT or AST are elevated but are less than 3 times the upper limit of normal then:

- Continue the statin and repeat in a month.
- If they remain elevated but are less than 3 times the upper limit of normal then continue statin and repeat again in 6 months.

## TITRATION THRESHOLD / TARGETS

	NICE titration threshold	JBS3
Primary prevention	Intensify lipid lowering therapy if: non-HDL-C reduction from baseline is less than 40%	non-HDL-C <2.5mmol/L (LDL-C <1.8mmol/L)
Secondary Prevention		
FH	Optimise lipid lowering therapy to achieve at least 50% reduction in LDL-C (or Non-HDL-cholesterol.)	

If baseline cholesterol is unknown in the setting of secondary prevention use the use Joint British Societies' JBS3 consensus recommendation.

**Non-HDL-C** = TC minus HDL-C

**LDL-C** = non-HDL-C minus (Fasting triglycerides<sup>a</sup>/2.2)

<sup>a</sup> valid only when fasting triglycerides are less than 4.5 mmol/L

## SPECIALIST SERVICES

Scope of specialist service available locally may include; Lipid Clinic, PCSK9i clinic (offering initiation and subsequent follow up), FH Genetic Diagnosis and Cascade testing, Lipoprotein Apheresis service. NICE eligibility criteria for PCSK9i and fasting LDL-C thresholds are summarised below.

	Without CVD	With CVD	
		High risk <sup>1</sup>	Very high risk <sup>2</sup>
NICE TA393 Alirocumab			
NICE TA394 Evolocumab			
Primary non-FH or mixed dyslipidaemia	Not recommended	LDL C > 4.0 mmol/L	LDL C > 3.5 mmol/L
Primary heterozygous-FH	LDL C > 5.0 mmol/L	LDL C > 3.5 mmol/L	

<sup>1</sup> History of any of the following: ACS; coronary or other arterial revascularisation procedures; CHD, ischaemic stroke; PAD. <sup>2</sup> Recurrent CV events or CV events in more than 1 vascular bed (that is, polyvascular disease).

## TRIGLYCERIDES

Triglyceride concentration	Action
Greater than 20mmol/L	<b>Refer to lipid clinic for urgent specialist review</b> if not a result of excess alcohol or poor glycaemic control. At risk of acute pancreatitis.
10 - 20mmol/L	Repeat the TG measurement with a fasting test (after an interval of 5 days, but within 2 weeks) and review for potential secondary causes of hyperlipidaemia. Seek specialist advice if the TG concentration remains > 10mmol/litre. At risk of acute pancreatitis
4.5 - 9.9mmol/L	If non-fasting triglycerides are greater than 4.5mmol/L, repeat with a fasting TG measurement. Be aware that the CVD risk may be underestimated by risk assessment tools, optimise the management of other CVD risk factors present and seek specialist advice if non-HDL-C concentration is > 7.5 mmol/litre.

## STATIN INTOLERANCE

Statin Intolerance is defined as the presence of clinically significant adverse effects from statin therapy that are considered to represent an unacceptable risk to the patient or that may result in adherence to therapy being compromised.

For people who are intolerant of the recommended statin treatment see the NHSE AAC statin intolerance algorithm, available on the NHSE AAC page ([Click here](#))

### References:

- JBS3. 2014. [www.jbs3risk.com/pages/6.htm](http://www.jbs3risk.com/pages/6.htm)
- Kirsten *et al.* 2005. Hospital Pharmacy 40(8):687-692
- Navarese *et al.* 2015. Annals of internal medicine 163(1):40-51
- Soon Jun Hong *et al.* 2018. Clinical therapeutics 40(2): 226-241.e4
- NICE. 2016. TA385 [www.nice.org.uk/guidance/ta385](http://www.nice.org.uk/guidance/ta385)
- NICE. 2016. TA393 [www.nice.org.uk/guidance/TA393](http://www.nice.org.uk/guidance/TA393)
- NICE. 2016. TA394 [www.nice.org.uk/guidance/TA394](http://www.nice.org.uk/guidance/TA394)
- NICE. 2014. CG181 [www.nice.org.uk/guidance/CG181](http://www.nice.org.uk/guidance/CG181)
- NICE. 2008. CG71 [www.nice.org.uk/guidance/cg71](http://www.nice.org.uk/guidance/cg71)
- NICE 2021. TA694 [www.nice.org.uk/guidance/TA694](http://www.nice.org.uk/guidance/TA694)

ACCELERATED  
ACCESS  
COLLABORATIVE

NHS

Approved by the National Institute for Health and Care Excellence (NICE), July 2021.